FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3145237130> ?p ?o ?g. }

• W3145237130 endingPage "1050" @default.
• W3145237130 startingPage "1038" @default.
• W3145237130 abstract "This was a Japanese subpopulation analysis of MONARCH 2, a double-blind, randomized, placebo-controlled, phase 3 study of abemaciclib plus fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer (ABC).Eligible women had progressed on (neo)adjuvant endocrine therapy (ET), ≤ 12 months from end of adjuvant ET, or on first-line ET for ABC, and had not received chemotherapy for ABC. Patients were randomized 2:1 to receive abemaciclib or placebo plus fulvestrant. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), pharmacokinetics (PK), health-related quality of life (HRQoL), and safety.In Japan, 95 patients were randomized (abemaciclib, n = 64; placebo, n = 31). At final PFS analysis (February 14, 2017), median PFS was 21.2 and 14.3 months, respectively, in the abemaciclib and placebo groups (hazard ratio: 0.672; 95% confidence interval: 0.380-1.189). Abemaciclib had a higher objective response rate (37.5%) than placebo (12.9%). PK and safety profiles for Japanese patients were consistent with those of the overall population, without clinically meaningful differences across most HRQoL dimensions evaluated. The most frequent adverse events in the abemaciclib versus placebo groups were diarrhea (95.2 versus 25.8%), neutropenia (79.4 versus 0%), and leukopenia (66.7 versus 0%). At a second data cutoff (June 20, 2019), median OS was not reached with abemaciclib and 47.3 months with placebo (hazard ratio: 0.755; 95% confidence interval: 0.390-1.463).Results of the Japanese subpopulation were consistent with the improved clinical outcomes and manageable safety profile observed in the overall population.NCT02107703; U.S. National Library of Medicine: https://clinicaltrials.gov/ct2/show/NCT02107703 ." @default.
• W3145237130 created "2021-04-13" @default.
• W3145237130 creator A5008549101 @default.
• W3145237130 creator A5008946028 @default.
• W3145237130 creator A5010399021 @default.
• W3145237130 creator A5016077305 @default.
• W3145237130 creator A5021782707 @default.
• W3145237130 creator A5036465305 @default.
• W3145237130 creator A5054758865 @default.
• W3145237130 creator A5066769011 @default.
• W3145237130 creator A5067189124 @default.
• W3145237130 creator A5071189878 @default.
• W3145237130 creator A5075605825 @default.
• W3145237130 creator A5076961942 @default.
• W3145237130 creator A5085618006 @default.
• W3145237130 creator A5089829213 @default.
• W3145237130 creator A5091087439 @default.
• W3145237130 creator A5091245889 @default.
• W3145237130 date "2021-04-01" @default.
• W3145237130 modified "2023-10-18" @default.
• W3145237130 title "Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy" @default.
• W3145237130 cites W1464936406 @default.
• W3145237130 cites W1848007259 @default.
• W3145237130 cites W1947168884 @default.
• W3145237130 cites W1991601194 @default.
• W3145237130 cites W2012502745 @default.
• W3145237130 cites W2019607817 @default.
• W3145237130 cites W2167571044 @default.
• W3145237130 cites W2318697345 @default.
• W3145237130 cites W2402797587 @default.
• W3145237130 cites W2404884142 @default.
• W3145237130 cites W2528767298 @default.
• W3145237130 cites W2552099557 @default.
• W3145237130 cites W2560635244 @default.
• W3145237130 cites W2612124029 @default.
• W3145237130 cites W2617437931 @default.
• W3145237130 cites W2618869843 @default.
• W3145237130 cites W2620993107 @default.
• W3145237130 cites W2763875663 @default.
• W3145237130 cites W2798042703 @default.
• W3145237130 cites W2805575723 @default.
• W3145237130 cites W2896600370 @default.
• W3145237130 cites W2896846857 @default.
• W3145237130 cites W2898684787 @default.
• W3145237130 cites W2900546561 @default.
• W3145237130 cites W2945884415 @default.
• W3145237130 cites W2948069739 @default.
• W3145237130 cites W2976415870 @default.
• W3145237130 cites W2980894934 @default.
• W3145237130 cites W2981679955 @default.
• W3145237130 cites W3010575887 @default.
• W3145237130 cites W3016908890 @default.
• W3145237130 cites W3039004318 @default.
• W3145237130 cites W3043217566 @default.
• W3145237130 cites W3133509869 @default.
• W3145237130 cites W4293241248 @default.
• W3145237130 doi "https://doi.org/10.1007/s12282-021-01239-8" @default.
• W3145237130 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8354907" @default.
• W3145237130 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33797023" @default.
• W3145237130 hasPublicationYear "2021" @default.
• W3145237130 type Work @default.
• W3145237130 sameAs 3145237130 @default.
• W3145237130 citedByCount "10" @default.
• W3145237130 countsByYear W31452371302021 @default.
• W3145237130 countsByYear W31452371302022 @default.
• W3145237130 countsByYear W31452371302023 @default.
• W3145237130 crossrefType "journal-article" @default.
• W3145237130 hasAuthorship W3145237130A5008549101 @default.
• W3145237130 hasAuthorship W3145237130A5008946028 @default.
• W3145237130 hasAuthorship W3145237130A5010399021 @default.
• W3145237130 hasAuthorship W3145237130A5016077305 @default.
• W3145237130 hasAuthorship W3145237130A5021782707 @default.
• W3145237130 hasAuthorship W3145237130A5036465305 @default.
• W3145237130 hasAuthorship W3145237130A5054758865 @default.
• W3145237130 hasAuthorship W3145237130A5066769011 @default.
• W3145237130 hasAuthorship W3145237130A5067189124 @default.
• W3145237130 hasAuthorship W3145237130A5071189878 @default.
• W3145237130 hasAuthorship W3145237130A5075605825 @default.
• W3145237130 hasAuthorship W3145237130A5076961942 @default.
• W3145237130 hasAuthorship W3145237130A5085618006 @default.
• W3145237130 hasAuthorship W3145237130A5089829213 @default.
• W3145237130 hasAuthorship W3145237130A5091087439 @default.
• W3145237130 hasAuthorship W3145237130A5091245889 @default.
• W3145237130 hasBestOaLocation W31452371301 @default.
• W3145237130 hasConcept C121608353 @default.
• W3145237130 hasConcept C126322002 @default.
• W3145237130 hasConcept C142724271 @default.
• W3145237130 hasConcept C143998085 @default.
• W3145237130 hasConcept C168563851 @default.
• W3145237130 hasConcept C197934379 @default.
• W3145237130 hasConcept C203092338 @default.
• W3145237130 hasConcept C204787440 @default.
• W3145237130 hasConcept C207103383 @default.
• W3145237130 hasConcept C27081682 @default.
• W3145237130 hasConcept C2775930923 @default.
• W3145237130 hasConcept C2780482068 @default.
• W3145237130 hasConcept C2908647359 @default.
• W3145237130 hasConcept C44249647 @default.

• next